Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALOPRIM vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
FDA-approved: Management of hyperuricemia in gout, management of hyperuricemia in patients with recurrent uric acid stones, and prevention of tumor lysis syndrome in patients receiving chemotherapy.,Off-label: Prevention of calcium oxalate calculi, management of hyperuricemia in patients with renal impairment, and treatment of Lesch-Nyhan syndrome.
Management of mild to moderate pain,Reduction of fever
300 mg orally once daily; may be increased to 600-800 mg/day in divided doses for severe gout.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Allopurinol: 1-2 h; Oxypurinol: 18-30 h (prolonged in renal impairment, up to 7 days in severe CKD)
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Allopurinol is metabolized primarily by xanthine oxidase to its active metabolite, oxypurinol. Both allopurinol and oxypurinol are further metabolized to a lesser extent by aldehyde oxidase.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Renal: ~70% (30% as allopurinol, 40% as oxypurinol); fecal: ~20%; biliary: minor (<5%)
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
Allopurinol: <1%; Oxypurinol: ~20% (primarily to albumin)
10-25% bound to albumin at therapeutic concentrations.
Allopurinol: 0.6-1.6 L/kg (suggests distribution in total body water); Oxypurinol: 0.6-1.0 L/kg
0.8-1.0 L/kg; suggests distribution into total body water.
Oral: 67-90% (allopurinol); rapidly converted to oxypurinol
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
GFR 30-60 m L/min: start at 200 mg/day; GFR 10-29 m L/min: 100 mg/day; GFR <10 m L/min: 100 mg every other day or 50 mg/day.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
No specific adjustment recommended; use with caution in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Children 10-20 mg/kg/day in 2-3 divided doses, maximum 400 mg/day.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Initiate at lower doses (e.g., 100 mg/day) due to age-related renal decline; monitor for adverse effects.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
Allopurinol has been associated with hypersensitivity reactions including severe skin reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening. The risk is higher in patients with renal impairment and those receiving thiazide diuretics. Discontinue at first sign of rash or other signs of hypersensitivity.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Risk of severe hypersensitivity reactions including SJS/TEN; increased risk in patients with renal impairment or concomitant thiazide use. Monitor for rash. Acute gout attacks may increase during early therapy; prophylaxis with colchicine or NSAIDs is recommended. Hepatic and renal function should be monitored. May cause drowsiness or dizziness.
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Absolute: Patients with a history of a severe hypersensitivity reaction to allopurinol. Relative: Renal impairment (dose adjustment needed), pregnancy (only if benefit outweighs risk), and lactation (use caution).
Hypersensitivity to acetaminophen or any component of the formulation
Avoid high-purine foods (e.g., organ meats, anchovies, sardines, mussels, scallops, red meat, beer) as they may increase serum uric acid levels and reduce drug efficacy. Maintain adequate hydration to prevent urate nephropathy. Grapefruit juice has no known interaction. No significant interaction with caffeine.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
First trimester: No evidence of teratogenicity in humans; animal studies show no fetal harm. Second/third trimester: No known risks; allopurinol crosses placenta but no congenital anomalies reported. Postnatal: No adverse effects reported.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Allopurinol and its metabolite oxypurinol are excreted in breast milk; M/P ratio not established. No adverse effects reported in nursing infants. Use with caution, especially in infants with G6PD deficiency.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
No dose adjustment required based on pregnancy alone. However, dose may need adjustment if renal function declines. Allopurinol pharmacokinetics not significantly altered in pregnancy; maintain dose based on renal function and uric acid levels.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Initiate therapy after acute gout flare has subsided; consider gradual dose titration to reduce flare risk; monitor for hypersensitivity reactions, especially in patients with renal impairment; use with caution in patients on thiazide diuretics or ACE inhibitors due to increased risk of hypersensitivity; assess renal function before starting and during therapy; adjust dose in renal impairment (Cr Cl <60 m L/min); avoid use with azathioprine or mercaptopurine unless dose reduction of these agents is implemented; educate patient to report rash, fever, or lymphadenopathy immediately.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Take this medication exactly as prescribed, usually once daily.,Do not start or stop taking this medication during an acute gout attack; wait until the flare has resolved.,Drink plenty of fluids (at least 2 liters of water per day) unless otherwise directed by your doctor.,Avoid alcohol and foods high in purines (e.g., red meat, organ meats, shellfish) as they may increase uric acid levels.,Report any skin rash, itching, swelling, or difficulty breathing to your doctor immediately.,Inform your doctor of all medications you are taking, including over-the-counter drugs and supplements.,Do not take this medication with azathioprine, mercaptopurine, or theophylline unless specifically instructed by your doctor.,Store at room temperature away from moisture and heat.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALOPRIM vs INJECTAPAP, answered by our medical review team.
ALOPRIM is a Xanthine Oxidase Inhibitor that works by Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALOPRIM and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALOPRIM is: 300 mg orally once daily; may be increased to 600-800 mg/day in divided doses for severe gout.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALOPRIM and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALOPRIM is classified as Category C. First trimester: No evidence of teratogenicity in humans; animal studies show no fetal harm. Second/third trimester: No known risks; allopurinol crosses placenta but no congenital . INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.